Perspective Therapeutics, Inc.

Perspective Therapeutics develops precision targeted alpha therapies (TAT) for cancer treatment. The company's pipeline focuses on alpha-emitting radiopharmaceuticals designed to deliver targeted radiation directly to cancer cells while minimizing damage to healthy tissue. Lead candidates include VMT-a-NET, in Phase 1/2a trials for neuroendocrine tumors expressing somatostatin receptor type 2; VMT01, also in Phase 1/2a development for MC1R-positive metastatic melanoma; PSV359, targeting fibroblast activation protein alpha; and PSV4XX, a prostate-specific membrane antigen-targeted therapy. The company maintains a clinical collaboration with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab.

As a clinical-stage therapeutic company, Perspective Therapeutics operates primarily in research and development with no marketed products generating revenue. The organization is headquartered in Seattle, Washington, with 138 full-time employees. Founded in 2004 as Isoray, Inc., the company rebranded as Perspective Therapeutics in February 2022. The company is incorporated in Delaware and trades on the NYSE.